Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.
Ganciclovir and foscarnet possess substantial activity against cytomegalovirus. Both exhibit dose-limiting toxicity, which reduces their clinical usefulness. We demonstrated synergistic inhibition of cytomegalovirus replication in vitro by ganciclovir and foscarnet. Reduced-dose combination therapy may provide a means to treat patients with cytomegalovirus infection while reducing drug toxicity.
Manischewitz
J F
JF
Laboratory of Herpesvirus Research, Food and Drug Administration, Bethesda, Maryland 20892.
Quinnan
G V
GV
Lane
H C
HC
Wittek
A E
AE
D003587:Cytomegalovirus / Q000187:drug effects* / Q000502:physiology; D004279:DNA, Viral / Q000096:biosynthesis; D004357:Drug Synergism; D017245:Foscarnet; D015774:Ganciclovir / Q000494:pharmacology*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects*
D004279:DNA, Viral; D017245:Foscarnet; D010746:Phosphonoacetic Acid; D015774:Ganciclovir